An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
ADOCIA Announces Its Annual Shareholders’ Meeting to Be Held on May 11, 2023 in Paris
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Adocia, a clinical-stage biopharmaceutical company specializing in diabetes and metabolic disease treatments, announced its annual shareholders' meeting scheduled for May 11, 2023, at 10.00 am in Paris. The meeting notice was published on April 5, 2023, and includes the agenda, proposed resolutions, and participation instructions. Shareholders must register their shares two business days prior to the meeting. Documentation related to the meeting is available on Adocia's website. Adocia holds over 25 patent families and has developed technologies like BioChaperone® for insulin products and AdOral® for oral peptide delivery. The company was ranked among the top SMEs in patent filings in France in recent years and employs approximately 115 people.
Positive
Scheduled AGM for shareholders on May 11, 2023, indicating ongoing shareholder engagement.
Development of innovative technologies like BioChaperone® and AdOral® shows strong R&D focus.
Ranked 4th and 7th in patent filings in 2019 and 2020 reflects strong intellectual property position.
Negative
None.
LYON, France--(BUSINESS WIRE)--
Regulatory News:
Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, announced today that it will hold its annual shareholders’ meeting (“AGM”) on May 11, 2023, at 10.00 am at Hotel de Talleyrand, in the offices of Jones Day, 2 rue Saint Florentin, 75001 Paris.
The notice of this shareholders’ meeting serving as convening notice was published on Wednesday, April 5th 2023, in the French Bulletin des Annonces Légales Obligatoires (“BALO”), and includes the agenda, the proposed resolutions as well as instructions to participate and vote for this meeting.
All documentation concerning the meeting is available to shareholders in accordance with the conditions set out in the regulations in force, and is available on the Company's website:
Only shareholders having registered their shares at least two business days prior to the date of the AGM, by midnight Paris time, will be able to participate physically in the AGM. Shareholders holding bearer shares (“actions au porteur”) will need to obtain a certificate of shareholding (“attestation de participation”) from their brokers. This certificate must be attached to the proxy form or to the appropriate voting form if shareholders wish to designate a proxy or vote by post. The “attestation de participation” may replace the admission card for shareholders wishing to attend the AGM in person.
Each shareholder may submit a question in writing to the Board of Directors, this question being treated during the shareholders meeting. Questions should be sent by registered mail with return receipt to the following address: ADOCIA, 115 avenue Lacassagne - 69003 Lyon or electronic communication to the following address: ag2023@adocia.com. The written question must imperatively be accompanied by a certificate of attendance in order to be treated and must be sent no later than the fourth business day preceding the date of the shareholders’ meeting.
About Adocia
Adocia is a biotechnology company specializing in the discovery and development of therapeutic solutions in the field of metabolic diseases, primarily diabetes and obesity. The company has a broad portfolio of drug candidates based on three proprietary technology platforms:
1) The BioChaperone® technology for the development of new generation insulins and products combining insulins with other classes of hormones; 2) AdOral®, an oral peptide delivery technology; 3) AdoShell®, an immunoprotective biomaterial for cell transplantation with a first application in pancreatic cells transplantation for patients with "brittle" diabetes.
Adocia holds more than 25 patent families and was ranked 4th and 7th in the French National Institute of Industrial Property (INPI) ranking of SMEs on the number of patents filed, in 2019 and 2020 respectively.
Based in Lyon, the company has approximately 115 employees. Adocia is listed on the EuronextTMParis market (Euronext: ADOC; ISIN: FR0011184241).
Disclaimer
This press release contains certain forward-looking statements concerning Adocia and its business. Such forward-looking statements are based on assumptions that Adocia considers as being reasonable. However, there can be no guarantee that the estimates contained in such forward-looking statements will be achieved, as such estimates are subject to numerous risks including those which are set forth in the “Risk Factors” section of the universal registration document that was filed with the French Autorité des marchés financiers on April 21, 2022 (a copy of which is available at www.adocia.com), in particular uncertainties that are linked to research and development, future clinical data, analyses, and the evolution of the economic context, the financial markets and the markets in which Adocia operates.
The forward-looking statements contained in this press release are also subject to risks not yet known to Adocia or not considered as material by Adocia as of this day. The occurrence of all or part of such risks could cause that actual results, financial conditions, performances, or achievements of Adocia be materially different from those mentioned in the forward-looking statements.
This press release and the information contained herein do not constitute an offer to sell or the solicitation of an offer to buy Adocia’s shares in any jurisdiction.
Adocia Press and Investors Relations
Ulysse Communication
Pierre-Louis Germain Margaux Puech Pays d’Alissac
Bruno Arabian adocia@ulysse-communication.com / + 33 (0)6 64 79 97 51
Source: ADOCIA
FAQ
When is Adocia's annual shareholders' meeting scheduled?
Adocia's annual shareholders' meeting is scheduled for May 11, 2023, at 10.00 am.
How can shareholders participate in the Adocia AGM?
Shareholders must register their shares at least two business days prior to the AGM and may need a certificate of shareholding if holding bearer shares.
What technologies does Adocia specialize in?
Adocia specializes in developing therapeutic solutions for diabetes and metabolic diseases, including technologies like BioChaperone® and AdOral®.
What is Adocia's patent filing ranking?
Adocia was ranked 4th and 7th in patent filings among SMEs in France in 2019 and 2020, respectively.
Where can shareholders find documentation for the AGM?
All AGM documentation is available on Adocia's website as stated in the notice.
